John Varian
Xoma has made John Varian full CEO after he served as interim since August last year.
Varian, a board member at Xoma since 2008, is in place in time for the firm’s growth plans for its gevokizumab – a potent monoclonal antibody for the treatment of inflammatory diseases.
"I accepted the position as interim CEO to manage XOMA's operations temporarily until we identified a permanent leader for the company,” said Varian, adding that he developed a passion for the company over the four months.
He said: “I believe Xoma is only a few short years away from attaining real success, and I decided I wanted to be a major part of that process.”
